Announcement of Resolutions of the 30th Meeting of the 11th Board of Directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 23rd Meeting of the 11th Board of Supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on receiving the Shanghai Stock Exchange's “Inquiry Letter on the Company's 2023 Annual Report Information Disclosure”
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on holding the 2023 annual results briefing
2023 Independent Director Debriefing Report (Gai Yongmei)
2023 Independent Director Debriefing Report (Zhao Xiang)
Opinions of the Board of Supervisors on the “Special Instructions of the Board of Directors on the Issuance of Internal Control Audit Reports by Accounting Firms with Unqualified Opinions on Highlighted Matters”
Announcement of Resolutions of the 29th Meeting of the 11th Board of Directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 22nd Meeting of the 11th Board of Supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on the estimated amount of comprehensive financial credit and external guarantee for the company in 2024
2023 Audit Report
Special note by the board of directors on internal control audit reports issued by accounting firms with unqualified opinions on key points
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2023 Annual Audit Accounting Firm Performance Evaluation Report
Special inspection opinion on the 2023 operating income deduction situation of Hangzhou Tianmusan Pharmaceutical Co., Ltd.
Special Opinions of the Board of Directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the 2023 Independent Directors' Independence Self-Inspection Report
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on changes in accounting policies
Special explanation on the 2023 non-operating capital occupation and other related capital transactions of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
2023 Independent Director Debriefing Report (Pei Yang)
Special note by the board of directors on matters relating to the issuance of unqualified audit reports by accounting firms with significant uncertainties in continuing operations
Special instructions on issuing an unqualified audit report with explanatory notes on the 2023 financial statements of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
No Data